Levels of ATM, AMFR, CD109, and SOS1 were all significantly higher (p < 0.001) in plasma samples from either stage 0, stage I/II, or stage III/IV melanoma patients than in healthy controls (Figure 3b–e, respectively), consistent with the NGS data (Table A1). This evidence concerns the gene AMFR and melanoma.